Aytu Biopharma (AYTU) Change in Receivables (2016 - 2026)
Aytu Biopharma has reported Change in Receivables over the past 11 years, most recently at -$2.3 million for Q4 2025.
- Quarterly Change in Receivables fell 201.32% to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, up 212.67% year-over-year, with the annual reading at $7.6 million for FY2025, 246.68% up from the prior year.
- Change in Receivables was -$2.3 million for Q4 2025 at Aytu Biopharma, down from $2.1 million in the prior quarter.
- Over five years, Change in Receivables peaked at $10.5 million in Q1 2025 and troughed at -$6.5 million in Q3 2021.
- The 5-year median for Change in Receivables is -$118000.0 (2023), against an average of $120894.7.
- Year-over-year, Change in Receivables crashed 2775.45% in 2022 and then skyrocketed 2025.42% in 2024.
- A 5-year view of Change in Receivables shows it stood at $1.3 million in 2021, then tumbled by 277.6% to -$2.4 million in 2022, then skyrocketed by 95.04% to -$118000.0 in 2023, then skyrocketed by 2025.42% to $2.3 million in 2024, then crashed by 201.32% to -$2.3 million in 2025.
- Per Business Quant, the three most recent readings for AYTU's Change in Receivables are -$2.3 million (Q4 2025), $2.1 million (Q3 2025), and -$4.7 million (Q2 2025).